BiomX Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders approved the issuance of common stock underlying Series Y preferred stock and warrants, as well as the potential adjournment to solicit more proxies if needed. Both proposals passed with sufficient votes, and management invited post-meeting questions.
-
The meeting was adjourned due to not reaching quorum and rescheduled for March 11, 2026. Stockholders who have already voted do not need to vote again unless they wish to change their vote.
Fiscal Year 2025
-
Q3 2025 saw key clinical and regulatory progress for BX004 and BX011, with BX004's U.S. trial paused due to a device issue but European enrollment ongoing. Financials show a $9.2M net loss and cash runway into Q1 2026, while positive FDA feedback supports both programs' advancement.
-
Advanced clinical programs for BX004 and BX211, with BX004 Phase 2B dosing initiated and strong financial management extending cash runway into Q1 2026. BX211 showed significant efficacy, and both programs are progressing toward key regulatory milestones.
-
Positive phase II results for BX211 in DFO and $12M financing strengthen the pipeline, with BX004 for cystic fibrosis on track for a Q1 2026 readout. Cash runway extends into Q1 2026, and regulatory discussions for pivotal trials are planned.
-
Leading experts presented compelling phase 2 data for a phage therapy in diabetic foot osteomyelitis, showing significant improvements in ulcer healing and safety over standard care. The therapy targets antibiotic-resistant infections and biofilms, with broad potential for future indications.
Fiscal Year 2024
-
BX211 achieved statistically significant efficacy and safety in a phase II DFO trial, marking a milestone for phage therapy. $12M in new financing supports ongoing clinical programs, with key data readouts and regulatory discussions expected in 2026.
-
BX211 phase II trial in DFO completed enrollment with results expected Q1 2025, while BX004 phase II-B was delayed to H1 2026 due to manufacturing scale-up. Q3 saw a net income of $9.6M, $24.7M in cash, and continued strong support for phage therapy programs.
-
The event highlighted a leading phage therapy company's recent merger, robust financing, and two advanced clinical programs targeting cystic fibrosis and diabetic foot osteomyelitis, both with significant market potential and upcoming Phase II readouts in 2025.
-
Merger with APT and $50M financing strengthened the pipeline and balance sheet. BX004 and BX211 clinical programs are progressing, with key data readouts expected in 2025. Cash runway extends through Q4 2025, and a 1-for-10 reverse stock split is set for August 26, 2024.